Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The only medications infants received during the study period were caffeine (63.5%), Vitamin D3 (60.9%), ferrous sulfate (60.9%) and bifidobacterium infantis (probiotic, 45%), with no significant differences (p < 0.05) in exposure rate between eCPAP and dCPAP infants.Demographic and physiological parameters of infants.eCPAPdCPAPeCPAP/dCPAP(n = 33)(n = 31)foldpDemographicsGestational Age (wk)29.8/1.730.2/2.00.990.34Birth Weight (g)1458/3181501/3410.970.60White/Black/Hispanic/Asian20/0/6/315/3/4/20.34Sex (m/f)22/1115/160.21Age Randomization (days)13.9/12.413.1/15.81.060.28Age Sample Collected (days)24.7/13.122.9/16.31.080.62Interval Randomize/Sample (days)10.8/2.79.8/5.11.100.31Antibiotic Treatment510.20Bronchopulmonary dysplasia12NSPhysiologicalFRC day 0 (ml)42.2/1044.3/10.10.950.95FRC day 14 (ml)55.8/11.549.8/8.11.120.02FRC change day 0-14 (ml)13.7/9.05.6/10.52.450.002FRC change day 0-14 (%)35.5/25.716.9/25.72.100.006Weight day 0 (g)1561/2371595/2530.980.58Weight change day 0-14 (%)31.8/7.128.2/6.01.130.031Caloric intake day 0-14 (kcal/kg/day)126.7/9.8127.3/8.61.020.19Lung diffusion capacity at 7 mo (ml/min/mmHg)3.53/0.942.59/0.941.360.0002Alveolar volume at 7 mo (ml)521/145387/1451.350.0007Mean/SD.Statistics by Student’s unpaired t test, Mann Whitney test or Fisher exact test.p values < 0.05 in bold.FRC functional residual capacity.

Source: Infant characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Single-blind reported · Research setting awaiting verification

Reported blinded roles: assessors.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

An investigator-initiated, single-center, single-blind RCT was conducted in the Oregon Health & Science University (OHSU) level IV neonatal intensive care unit (NICU), evaluating lung function at 6 months corrected age as the primary outcome (NCT#0429556).

Source: Methods.

The clinical team, outcome assessors, and statistician, however, were blinded to allocation.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Metabolic response to extended continuous positive airway pressure in premature infants

Study design awaiting verification · Pediatric Research · 2025

Original publication title

Metabolic response to extended continuous positive airway pressure in premature infants

Philip L. Ballard; Kelvin D. MacDonald; Julia Harris; Thaybeth I. Malave-Mendez; Mitzi Go; Alec Martin; Kristin Milner; Cheryl Chapin; Robert Tepper; Dara G. Torgerson; Cindy T. McEvoy

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Discontinuation of CPAP altered the blood metabolome and impaired gain in FRC and weight. Extending CPAP may reduce the work of breathing, improve mitochondrial utilization of fatty acids, and provide more energy for lung and body growth.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Assess the impact of extended CPAP (eCPAP) on the metabolomic profile and relationship to lung function.

Source: Objective

Abstract: Design/methods

Infants ≤32 weeks’ gestational age were randomized to bubble eCPAP with room air or discontinued CPAP (dCPAP). Functional residual capacity (FRC) was measured at randomization and at 2 weeks. Blood samples obtained during treatment were subjected to UHPLC:MS/MS (Metabolon Inc.) and metabolomic data were analyzed by ANCOVA.

Source: Design/methods

Abstract: Impact

  • Discontinuing CPAP in premature infants recovering from respiratory distress altered levels of 14% of detected blood metabolites within 1 week and reduced gain in lung function and body weight at 2 weeks.

  • Biochemical sub pathway enrichment occurred for acylcarnitines with higher circulating levels of 22 fatty acid metabolites in infants coming off CPAP.

  • Extending CPAP beyond the current guidelines for discontinuation may reduce the work of breathing, improve mitochondrial utilization of fatty acids, and provide more energy for lung development and body growth.

Source: Impact

Abstract: Results

eCPAP infants had greater increases in both FRC (2.1-fold, p = 0.005) and weight (1.13-fold, p = 0.03). Of 1230 total metabolites detected, levels of 87 were higher at p < 0.05 and 75 were lower in eCPAP infants. A new plateau level for key metabolites occurred at 5 ± 2 days after discontinuing CPAP. Sub pathway enrichment (p < 0.05) occurred for bilirubin degradation products (7.7-fold) and acylcarnitines (3.5-fold), all higher in dCPAP. Blood levels of some metabolites were correlated with FRC and weight gain.

Source: Results

Abstract: Conclusion

Discontinuation of CPAP altered the blood metabolome and impaired gain in FRC and weight. Extending CPAP may reduce the work of breathing, improve mitochondrial utilization of fatty acids, and provide more energy for lung and body growth.

Source: Conclusion
Authors’ abstract

Background

Extending the duration of continuous positive airway pressure (CPAP) in preterm infants with respiratory distress may improve lung function.

Objective

Assess the impact of extended CPAP (eCPAP) on the metabolomic profile and relationship to lung function.

Design/methods

Infants ≤32 weeks’ gestational age were randomized to bubble eCPAP with room air or discontinued CPAP (dCPAP). Functional residual capacity (FRC) was measured at randomization and at 2 weeks. Blood samples obtained during treatment were subjected to UHPLC:MS/MS (Metabolon Inc.) and metabolomic data were analyzed by ANCOVA.

Results

eCPAP infants had greater increases in both FRC (2.1-fold, p = 0.005) and weight (1.13-fold, p = 0.03). Of 1230 total metabolites detected, levels of 87 were higher at p < 0.05 and 75 were lower in eCPAP infants. A new plateau level for key metabolites occurred at 5 ± 2 days after discontinuing CPAP. Sub pathway enrichment (p < 0.05) occurred for bilirubin degradation products (7.7-fold) and acylcarnitines (3.5-fold), all higher in dCPAP. Blood levels of some metabolites were correlated with FRC and weight gain.

Conclusion

Discontinuation of CPAP altered the blood metabolome and impaired gain in FRC and weight. Extending CPAP may reduce the work of breathing, improve mitochondrial utilization of fatty acids, and provide more energy for lung and body growth.

Impact

  • Discontinuing CPAP in premature infants recovering from respiratory distress altered levels of 14% of detected blood metabolites within 1 week and reduced gain in lung function and body weight at 2 weeks.

  • Biochemical sub pathway enrichment occurred for acylcarnitines with higher circulating levels of 22 fatty acid metabolites in infants coming off CPAP.

  • Extending CPAP beyond the current guidelines for discontinuation may reduce the work of breathing, improve mitochondrial utilization of fatty acids, and provide more energy for lung development and body growth.

Publication and source details

Original title: Metabolic response to extended continuous positive airway pressure in premature infants

Philip L. Ballard; Kelvin D. MacDonald; Julia Harris; Thaybeth I. Malave-Mendez; Mitzi Go; Alec Martin; Kristin Milner; Cheryl Chapin; Robert Tepper; Dara G. Torgerson; Cindy T. McEvoy

Pediatric Research · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:02:35.726549+00:00

DOI: 10.1038/s41390-025-04670-1 · PMC13638474